Overview of non-epithelial ovarian tumours: Incidence and survival in the Netherlands

Aims: About 5% of ovarian tumours have a non-epithelial histology, including germ cell tumours (GCTs), sex cord-stromal tumours (SCSTs), and sarcomas. Since the rarity of these non-epithelial ovarian tumours and the scarcity of population-based studies, the aim of this population-based study is to describe trends in incidence, treatment, and survival of these women in the Netherlands.Methods: All Dutch women diagnosed with non-epithelial ovarian malignant tumours between 1989 and 2015 were identified from the Netherlands Cancer Registry. Demographics, tumour characteristics, and initial treatm... Mehr ...

Verfasser: Slangen, B.F.M
Dokumenttyp: OTHER_DOCUMENT
Erscheinungsdatum: 2017
Verlag/Hrsg.: Morressier
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-26812065
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://openresearchlibrary.org/viewer/07d3cef8-e0f3-4ea3-be93-fc5a348a4e33

Aims: About 5% of ovarian tumours have a non-epithelial histology, including germ cell tumours (GCTs), sex cord-stromal tumours (SCSTs), and sarcomas. Since the rarity of these non-epithelial ovarian tumours and the scarcity of population-based studies, the aim of this population-based study is to describe trends in incidence, treatment, and survival of these women in the Netherlands.Methods: All Dutch women diagnosed with non-epithelial ovarian malignant tumours between 1989 and 2015 were identified from the Netherlands Cancer Registry. Demographics, tumour characteristics, and initial treatment were collected and overall survival was analysed.Results: A total of 1258 women were diagnosed with non-epithelial ovarian tumours in the Netherlands, including 752 GCTs (60%), 341 SCSTs (27%), and 165 sarcomas (13%). The European age standardized incidence rate (ESR) was 0.4 per 100,000 persons per year for GCTs, 0.2 for SCSTs and 0.1 for sarcomas. Approximately 97% of patients underwent surgical resection for the primary tumour, whereas 31% received systemic treatment and 3% radiotherapy. Five-year overall survival improved for all histologic subtypes between the late 1980u2019s until 2015: GCTs from 73% to 88% (p=0.03) SCSTs from 64% to 81% (p=0.57) and sarcomas from 20% to 29% (p=0.14).Conclusion: Malignant GCTs and SCSTs are rare and its incidence did not significantly change during the last decades. They have a good prognosis which also improved slightly. Women with primary sarcomas of the ovary are extremely rare and still have a poor prognosis.